NYSE:SUZ 12 February 2026

March 28, 2026, 3:31 AM EDT. Stoke Therapeutics (STOK) stock surged 340% over the past year. On March 10, 2026, Chair Arthur Tzianabos sold 4,355 shares for about $174,000 by exercising stock options before immediate sale. This move reduced his direct shares by 12.2% to 31,339 but he retains 118,696 options, signaling potential future transactions tied to equity compensation rather than market sentiment. The company, valued at $1.9 billion, focuses on RNA-based medicines for severe genetic disorders, with lead candidates targeting Dravet syndrome and optic atrophy. Revenue stands at $184.4 million trailing twelve months, with a net loss of $6.9 million. The sale is driven by compensation exercise liquidity rather than a shift in confidence, underlining Stoke's long-term pipeline and rare disease market position.